The following summarizes the long-term treatment data presented at ECTRIMS 2018.

Teriflunomide: The long-term (up to 12.5 years) efficacy and safety of teriflunomide were examined in a pooled analysis of phase II and phase III trials and their extensions (Freedman et al. ECTRIMS 2018; abstract P1233); cumulative drug exposure was 1357 patient-years. The annualized relapse for patients treated with teriflunomide 14 mg was 0.38 vs. 0.59 with placebo. The proportion of patients with serious adverse events and the proportion discontinuing due to adverse events was comparable with teriflunomide and placebo (12.4% vs. 12.8%; and 6.9% vs. 13.1%, respectively). Read More

Controversies with revised 2017 McDonald criteria
Aggressive treatment is more effective, but…
Dimethyl fumarate – long-term data
Examining autoimmunity with alemtuzumab
2-minute walk more sensitive than T25FW Read More